Jain Global’s Structure Therapeutics GPCR Stock Holding History

Jain Global’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,772	Closed	-$278K	–	1873
2026 Q1	$278K	Sell	5,772 -94,224	-94%	-$6.45M	﹤0.01%	1033
2025 Q4	$6.95M	Buy	+99,996	New	+$4.08M	0.03%	384
2025 Q3	–	Sell	-69,369	Closed	-$1.44M	–	1214
2025 Q2	$1.44M	Buy	69,369 +45,730	+193%	+$1.01M	0.01%	568
2025 Q1	$409K	Buy	+23,639	New	+$579K	﹤0.01%	598

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jain Global's GPCR Position: Q2 2026 in Review

Jain Global sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 5,772 shares — an estimated $278K sold.

Jain Global first reported a position in GPCR in Q1 2025 and held it in 4 quarters. The position peaked at $6.95M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Jain Global reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
Jain Global sold 5,772 Structure Therapeutics shares in Q2 2026, an estimated $278K.
Jain Global first reported a position in Structure Therapeutics in Q1 2025 and held it in 4 quarters.
Jain Global's Structure Therapeutics position peaked at $6.95M in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.